169 related articles for article (PubMed ID: 35590334)
1. Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant.
Zhao C; Bartock M; Jia B; Shah N; Claxton DF; Wirk B; Rakszawski KL; Nickolich MS; Naik SG; Rybka WB; Ehmann WCC; Hohl RJ; Valentin J; Bernas-Peterson M; Gerber EM; Zimmerman M; Mierski JA; Mineishi S; Zheng H
J Hematol Oncol; 2022 May; 15(1):64. PubMed ID: 35590334
[TBL] [Abstract][Full Text] [Related]
2. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
[TBL] [Abstract][Full Text] [Related]
3. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
[TBL] [Abstract][Full Text] [Related]
4. Increased Infections and Delayed CD4
Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
[TBL] [Abstract][Full Text] [Related]
5. PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade.
Ikegawa S; Meguri Y; Kondo T; Sugiura H; Sando Y; Nakamura M; Iwamoto M; Maeda Y; Matsuoka KI
Blood Adv; 2019 Dec; 3(23):4081-4094. PubMed ID: 31821459
[TBL] [Abstract][Full Text] [Related]
6. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation.
Massoud R; Gagelmann N; Fritzsche-Friedland U; Zeck G; Heidenreich S; Wolschke C; Ayuk F; Christopeit M; Kröger N
Haematologica; 2022 Apr; 107(4):857-867. PubMed ID: 33832208
[TBL] [Abstract][Full Text] [Related]
7. Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model.
Makuuchi Y; Nakashima Y; Nishimoto M; Koh H; Hino M; Nakamae H
Exp Hematol; 2023 Jul; 123():56-65. PubMed ID: 37098360
[TBL] [Abstract][Full Text] [Related]
8. Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy.
Leserer S; Graf T; Franke M; Bogdanov R; Arrieta-Bolaños E; Buttkereit U; Leimkühler N; Fleischhauer K; Reinhardt HC; Beelen DW; Turki AT
Front Immunol; 2023; 14():1082727. PubMed ID: 37020562
[TBL] [Abstract][Full Text] [Related]
9. Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4
Hadjis AD; Nunes NS; Khan SM; Fletcher RE; Pohl AP; Venzon DJ; Eckhaus MA; Kanakry CG
Front Immunol; 2022; 13():796349. PubMed ID: 35242129
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
Montoro J; Roldán E; Piñana JL; Barba P; Chorão P; Quintero A; Hernani R; Ortí G; Lorenzo JI; Balaguer-Roselló A; Salamero O; Fox L; Solves P; Gómez I; Guerreiro M; Hernández Boluda JC; Sanz G; Solano C; Sanz MÁ; Valcárcel D; Sanz J
Eur J Haematol; 2021 Jan; 106(1):114-125. PubMed ID: 33025625
[TBL] [Abstract][Full Text] [Related]
11. Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.
Adhikary SR; Cuthbertson P; Nicholson L; Bird KM; Sligar C; Hu M; O'Connell PJ; Sluyter R; Alexander SI; Watson D
Immunology; 2021 Oct; 164(2):332-347. PubMed ID: 34021907
[TBL] [Abstract][Full Text] [Related]
12. Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.
Retière C; Willem C; Guillaume T; Vié H; Gautreau-Rolland L; Scotet E; Saulquin X; Gagne K; Béné MC; Imbert BM; Clemenceau B; Peterlin P; Garnier A; Chevallier P
Oncotarget; 2018 Feb; 9(14):11451-11464. PubMed ID: 29545911
[TBL] [Abstract][Full Text] [Related]
13. Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide.
Maeda Y
J Clin Exp Hematop; 2021 Mar; 61(1):1-9. PubMed ID: 33551435
[TBL] [Abstract][Full Text] [Related]
14. Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice.
Cuthbertson P; Button A; Sligar C; Elhage A; Vine KL; Watson D; Sluyter R
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339054
[TBL] [Abstract][Full Text] [Related]
15. Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects.
Patterson MT; Khan SM; Nunes NS; Fletcher RE; Bian J; Hadjis AD; Eckhaus MA; Mendu SK; de Paula Pohl A; Venzon DJ; Choo-Wosoba H; Ishii K; Qin H; Fry TJ; Cam M; Kanakry CG
Blood; 2023 Feb; 141(6):659-672. PubMed ID: 36201744
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide.
Sligar C; Cuthbertson P; Miles NA; Adhikary SR; Elhage A; Zhang G; Alexander SI; Sluyter R; Watson D
Immunol Cell Biol; 2023 Aug; 101(7):639-656. PubMed ID: 37191045
[TBL] [Abstract][Full Text] [Related]
17. [Research Progress of Post-Transplant Cyclophosphamide Combined with Antithymocyte Globulin in Preventing GVHD after Hematopoietic Stem Cell Transplantation --Review].
Wu MJ; Ye PP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1899-1904. PubMed ID: 38071080
[TBL] [Abstract][Full Text] [Related]
18. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models.
Wolf D; Bader CS; Barreras H; Copsel S; Pfeiffer BJ; Lightbourn CO; Altman NH; Komanduri KV; Levy RB
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333311
[TBL] [Abstract][Full Text] [Related]
19. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
Yang K; Fan ZP; Liu QF; Zhang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
Nunes NS; Kanakry CG
Front Immunol; 2019; 10():2668. PubMed ID: 31849930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
